
FDA: No Scientific Evidence That NSAID Use Worsens COVID-19 Symptoms
There is currently no scientific evidence suggesting that non-steroidal anti-inflammatory drug use could worsen COVID-19 in those infected.
Despite emerging reports that the use of non-steroidal anti-inflammatory drugs (NSAIDs) could exacerbate coronavirus disease (COVID-19), officials with the FDA have said that there is currently no available scientific evidence backing these reports at this time.1
In a published statement, the agency did indicate that it is investigating the issue and will communicate publicly when more information is available. However, as of now, the agency “is not aware of scientific evidence connecting the use of NSAIDs, like ibuprofen, with worsening COVID-19 symptoms.”
Last week, France’s health ministry urged individuals to avoid taking OTC NSAIDs, including ibuprofen, aspirin, and naproxen, suggesting that these drugs may increase the severity of COVID-19. As an alternative, those infected with the virus were advised to take acetaminophen, such as Tylenol, instead.2
A commentary previously published in
However, there is no published or peer-reviewed data to substantiate a potential interaction between NSAID use and COVID-19 symptoms.
In a
“We are also consulting with physicians treating COVID-19 patients and are not aware of reports of any negative effects of ibuprofen, beyond the usual known side effects that limit its use in certain populations,” the WHO added.
However, the FDA maintained that, “all prescription NSAID labels warn that ‘the pharmacological activity of NSAIDs in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.’”
References:
1. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19 [news release].
2. Snyder B. Ibuprofen and COVID-19: a doctor’s guidance [VUMC Reporter]. Vanderbilt University Medical Center’s website.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.